Fractyl Revenue and Competitors

Lexington,

Location

$310.2M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Fractyl's estimated annual revenue is currently $16.6M per year.(i)
  • Fractyl's estimated revenue per employee is $155,000
  • Fractyl's total funding is $310.2M.

Employee Data

  • Fractyl has 107 Employees.(i)
  • Fractyl grew their employee count by -8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$15.3M99-49%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.5M29-6%N/AN/A
#10
$9.6M62-7%N/AN/A
Add Company

Fractyl is a biotechnology firm dedicated to addressing metabolic disorders such as obesity and type 2 diabetes. This is accomplished through the development of novel therapies that target the underlying causes of these conditions, as opposed to merely treating their symptoms. Their primary emphasis is on the gastrointestinal tract and pancreas, with the objective of developing therapeutic interventions that rectify the fundamental pathology. Revita, a heat-based technique designed to enhance blood sugar regulation in diabetics, and Rejuva, an early-stage gene therapy platform, are both in their current pipeline. By doing so, they hope to revolutionize the treatment of metabolic diseases from chronic management to possible remedies, thereby saving lives and preventing the spread of these pervasive conditions. Check here for more information on how to align sales and revenue.

keywords:N/A

$310.2M

Total Funding

107

Number of Employees

$16.6M

Revenue (est)

-8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Fractyl News

2022-04-13 - Resetting Your Gut Could Lower Your Glucose Levels

Fractyl Health has developed a new technology called duodenal mucosal resurfacing, which can "reset" your gut, leading to improvements in...

2022-03-30 - Fractyl Health Announces FDA IDE Approval to Begin ...

Revitalize-2 is the second pivotal study for the Revita DMR® system (Revita®) in Fractyl Health's Revitalize T2D clinical development...

2021-06-17 - Fractyl Health collects $100M Series F

Fractyl Health has raised $100 million in a round co-led by Maverick Capital, M28 Capital and Population Health Partners. Based in the Boston area, the company is a developer of therapeutics for metabolic diseases. It plans to use the funds to advance clinical studies intended to reduce insulin ...

2021-06-16 - Fractyl Announces Closing of $100 Million Series F Financing to Expand Clinical Development Programs in Type 2 Diabetes

Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the closing of a $100 million Series F financing. The financing was led by new investors Maverick Capital, M28 Capital, and Populatio ...

2020-08-10 - Taiwania Capital leads $55m Series E round in Fractyl Laboratories

Premium Taiwania Capital Management Corporation has led a $55 million Series E financing round in Fractyl Laboratories Inc., a life sciences company focused on tackling metabolic diseases, according to an announcement. Continue reading this story with a subscription to DealStreetAsia. Subscri ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$19.4M10823%N/A
#2
$19.4M108-6%N/A
#3
$18.9M108-18%N/A
#4
$27M108-2%N/A
#5
$16.4M109-8%N/A